Get the Daily Brief
Latest Biotech News
Mammoth reveals monkey data: advancing in‑vivo triglyceride gene‑editing trial
Mammoth Biosciences disclosed non‑human primate data from its lead program showing durable triglyceride lowering after a single in‑vivo gene editing intervention, and announced plans to move the...
Ex‑Moderna leaders raise $325M: Ascenta Capital launches big biotech fund
Two former Moderna executives have closed Ascenta Capital’s inaugural biotech fund at $325 million, backing early‑stage life science investments. The fund, formed in 2023 and now publicly...
Nilo launches with $101M: brain‑to‑immune startup targets systemic inflammation
Nilo Therapeutics launched with a $101 million Series A to advance preclinical programs that target neural circuits controlling systemic immunity. The company, founded by academic neuro‑immunology...
Chiesi takes Arbor program: $2.1B option to build gene‑editing rare liver pipeline
Chiesi Group entered an exclusive collaboration and license with Arbor Biotechnologies to develop Arbor’s lead gene editing candidate ABO‑101 for primary hyperoxaluria type 1 (PH1) and to access...
Tessera awarded ARPA‑H funds: $41.3M to advance in‑vivo CAR‑T engineering
Tessera Therapeutics received up to $41.3 million from ARPA‑H to support its EMBODY program, which aims to develop in‑vivo CAR‑T approaches that engineer immune cells directly in patients. The...
Sanofi, Orano Med report phase‑2 win: AlphaMedix meets response endpoint in GEP‑NETs
Sanofi and partner Orano Med reported positive Phase 2 results for AlphaMedix, a targeted alpha‑emitting radiopharmaceutical in gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). In a...
Novo Nordisk buys Akero for fatty-liver drug – $4.7B upfront
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion upfront to secure a late-stage therapy for metabolic dysfunction–associated steatohepatitis (MASH). The deal, disclosed by Novo,...
AstraZeneca bets $555M on Algen’s CRISPR-AI platform for target discovery
AstraZeneca struck a multi-year research partnership valued at up to $555 million with Algen Biotechnologies to use Algen’s AlgenBrain platform — a CRISPR-enabled, AI-integrated functional...
Mammoth Biosciences shows monkey proof for in vivo triglyceride gene edit ... first human trial planned
Mammoth Biosciences disclosed non-human primate data for its lead in vivo gene editing program that aims to permanently lower triglycerides. The company presented monkey efficacy and safety...
Chiesi and Arbor ink up-to-$2.1B gene-editing pact for rare liver diseases
Chiesi Group entered an exclusive collaboration and license with Arbor Biotechnologies to develop and commercialize Arbor’s ABO-101, a liver-directed gene editing candidate for primary...
Ono’s EP4 antagonist with Opdivo meets primary PFS endpoint in phase 2 gastric cancer
Ono Pharmaceutical reported that ONO-4578, an EP4 receptor antagonist developed with Bristol Myers Squibb outside certain territories, hit the progression‑free survival (PFS) primary endpoint in a...
Sanofi’s AlphaMedix radiopharmaceutical hits phase 2 response goals in neuroendocrine tumors
Sanofi disclosed positive Phase 2 results for AlphaMedix, an alpha-emitting targeted radioligand therapy (developed with Orano Med/RadioMedix) for gastroenteropancreatic neuroendocrine tumors...
FDA amends Xeloda label: pre‑treatment DPYD genetic testing now recommended
The U.S. Food and Drug Administration updated the boxed warning for Genentech’s capecitabine (Xeloda) to explicitly recommend pre‑treatment DPYD genetic testing to identify patients with...
Intellia gives clinical update on in vivo gene editing programs at ESGCT
Intellia Therapeutics presented a clinical update at the ESGCT meeting reporting progress across its in vivo lipid nanoparticle (LNP) gene editing programs. CSO Birgit Schultes highlighted...
ARPA‑H funds seven teams to accelerate in‑vivo cell and gene therapies
The Advanced Research Projects Agency for Health (ARPA‑H) awarded funding to seven teams to advance in‑vivo therapies designed to program immune cells and other cell types directly inside the...
Lexeo’s Friedreich ataxia gene therapy eyed for accelerated approval path
Lexeo Therapeutics reported positive interim data for LX‑2006, a cardiomyopathy gene therapy for Friedreich ataxia, and said U.S. FDA discussions indicated the program may be eligible for an...
Chiesi-Arbor pact: up to $2.1B to develop liver gene editing
Chiesi Group and Arbor Biotechnologies agreed an exclusive collaboration and license to develop Arbor’s lead in vivo gene‑editing candidate ABO‑101 and access Arbor’s editing platform, in a deal...
Intellia clinical update: in vivo edits show durable knockdown
Intellia Therapeutics provided a clinical update on its in vivo lipid‑nanoparticle (LNP) gene‑editing programs at ESGCT, focusing on NTLA‑2002 and lonvo‑z. CSO Birgit Schultes reported that...
FDA clears Boehringer’s Jascayd: first new IPF drug in a decade
The U.S. Food and Drug Administration approved Boehringer Ingelheim’s nerandomilast, branded Jascayd, for idiopathic pulmonary fibrosis (IPF)—the first new FDA approval in the indication in over...
Sanofi’s AlphaMedix hits Phase 2 goals—alpha radioligand shows responses
Sanofi, working with Orano Med (and partners RadioMedix/Orano), reported that its alpha‑emitting radioligand AlphaMedix met primary endpoints in a Phase 2 study for unresectable or metastatic...